AidsmapEarly results from a small study suggest that twice-a-year injections of lenacapavir, an experimental HIV capsid inhibitor, can be used as part of a combination regimen for people starting HIV treatment, the 11th International AIDS Society Conference on HIV Science (IAS 2021) heard today.
On Saturday, aidsmap reported on CAPELLA, a study of lenacapavir in treatment-experienced people failing other regimens. Today, Professor Samir Gupta of Indiana University presented the first 28 weeks of efficacy and safety results from CALIBRATE, a study with 182 people new to HIV treatment, with baseline CD4 counts over 200. In these studies, lenacapavir was taken as a subcutaneous (under the skin) injection in the belly.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
TheBodyPro: Can long-acting regimens solve virologic failure in heavily treatment-experienced people with HIV?
-
[Press release] TaiMed Biologics completes Phase 2b enrollment for TMB-365/380 in HIV maintenance therapy study
-
Spotlight: South Africa’s ARV programme hardly grew in 2025, according to latest estimates
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.